Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
Nurix Therapeutics (NRIX), a clinical-stage biopharmaceutical company specializing in targeted protein degradation medicines, announced its participation in the upcoming RBC Capital Markets Global Healthcare Conference. The company's Chief Financial Officer Hans van Houte and Chief Business Officer Jason Kantor, Ph.D., will engage in a fireside chat on Wednesday, May 21, 2025, at 2:05 p.m. ET in New York, NY. The presentation will be available through a live webcast on Nurix's website in the Investors section, with the recording remaining accessible for 30 days following the event.
Nurix Therapeutics (NRIX), un'azienda biofarmaceutica in fase clinica specializzata in farmaci per la degradazione mirata delle proteine, ha annunciato la sua partecipazione alla prossima RBC Capital Markets Global Healthcare Conference. Il Direttore Finanziario Hans van Houte e il Direttore Commerciale Jason Kantor, Ph.D., parteciperanno a una conversazione informale mercoledì 21 maggio 2025 alle ore 14:05 ET a New York, NY. La presentazione sarà disponibile in diretta streaming sul sito web di Nurix nella sezione Investitori, con la registrazione accessibile per 30 giorni dopo l'evento.
Nurix Therapeutics (NRIX), una empresa biofarmacéutica en etapa clínica especializada en medicamentos para la degradación dirigida de proteínas, anunció su participación en la próxima RBC Capital Markets Global Healthcare Conference. El Director Financiero Hans van Houte y el Director de Negocios Jason Kantor, Ph.D., participarán en una charla informal el miércoles 21 de mayo de 2025 a las 2:05 p.m. ET en Nueva York, NY. La presentación estará disponible mediante una transmisión en vivo en el sitio web de Nurix en la sección de Inversores, y la grabación permanecerá accesible por 30 días después del evento.
Nurix Therapeutics (NRIX)는 표적 단백질 분해 의약품을 전문으로 하는 임상 단계의 생명공학 제약 회사로, 다가오는 RBC Capital Markets 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 최고재무책임자 한스 반 하우트(Hans van Houte)와 최고사업책임자 제이슨 칸토 박사(Jason Kantor, Ph.D.)가 2025년 5월 21일 수요일 오후 2시 5분(동부시간) 뉴욕에서 열린 파이어사이드 채팅에 참여할 예정입니다. 발표는 Nurix 웹사이트의 투자자 섹션에서 라이브 웹캐스트로 제공되며, 이벤트 후 30일 동안 녹화본을 시청할 수 있습니다.
Nurix Therapeutics (NRIX), une société biopharmaceutique en phase clinique spécialisée dans les médicaments de dégradation ciblée des protéines, a annoncé sa participation à la prochaine RBC Capital Markets Global Healthcare Conference. Le directeur financier Hans van Houte et le directeur des affaires Jason Kantor, Ph.D., participeront à une discussion informelle le mercredi 21 mai 2025 à 14h05 ET à New York, NY. La présentation sera disponible en webcast en direct sur le site internet de Nurix dans la section Investisseurs, avec un enregistrement accessible pendant 30 jours après l'événement.
Nurix Therapeutics (NRIX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf zielgerichtete Proteinabbau-Medikamente spezialisiert hat, gab seine Teilnahme an der bevorstehenden RBC Capital Markets Global Healthcare Conference bekannt. Der Finanzvorstand Hans van Houte und der Chief Business Officer Jason Kantor, Ph.D., werden am Mittwoch, den 21. Mai 2025, um 14:05 Uhr ET in New York, NY, an einem Kamin-Gespräch teilnehmen. Die Präsentation wird über einen Live-Webcast auf der Webseite von Nurix im Bereich Investoren verfügbar sein, wobei die Aufzeichnung für 30 Tage nach der Veranstaltung abrufbar bleibt.
- None.
- None.
SAN FRANCISCO, May 15, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Hans van Houte, chief financial officer of Nurix, and Jason Kantor, Ph.D., chief business officer of Nurix, will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 21, 2025, at 2:05 p.m. ET. The conference is being held in New York, NY.
The fireside chat will be webcast live and can be accessed via a link in the Investors section of the Nurix website. The archived webcast will be available for 30 days after the event.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix’s partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.
Contacts:
Investors
Kris Fortner
Nurix Therapeutics, Inc.
kfortner@nurixtx.com
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com
Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com
Kris Fortner
Nurix Therapeutics
Kfortner@nurixtx.com
FAQ
When is Nurix Therapeutics (NRIX) presenting at the RBC Capital Markets Healthcare Conference 2025?
Who will represent Nurix Therapeutics (NRIX) at the RBC Healthcare Conference 2025?
How can investors access Nurix Therapeutics' (NRIX) presentation at the RBC Healthcare Conference?
What is Nurix Therapeutics' (NRIX) main business focus?
